List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pyelonephritis - Overview
Pyelonephritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pyelonephritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pyelonephritis - Companies Involved in Therapeutics Development
Achaogen Inc (Inactive)
Allecra Therapeutics GmbH
Entasis Therapeutics Holdings Inc
Iterum Therapeutics Plc
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Nabriva Therapeutics Plc
Paratek Pharmaceuticals Inc
Pfizer Inc
Qilu Pharmaceutical Co Ltd
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
XuanZhu Biological Technology Co Ltd
Pyelonephritis - Drug Profiles
(AAI-101 + cefepime) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(avibactam sodium + ceftazidime) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cefepime + taniborbactam hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cefepime + zidebactam) - Drug Profile
Product Description
Mechanism Of Action
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(durlobactam sodium + sulbactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(meropenem + vaborbactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
benapenem - Drug Profile
Product Description
Mechanism Of Action
History of Events
ceforanide - Drug Profile
Product Description
Mechanism Of Action
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
History of Events
FL-058 - Drug Profile
Product Description
Mechanism Of Action
History of Events
fosfomycin disodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
nacubactam - Drug Profile
Product Description
Mechanism Of Action
History of Events
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
plazomicin sulfate - Drug Profile
Product Description
Mechanism Of Action
History of Events
sulopenem - Drug Profile
Product Description
Mechanism Of Action
History of Events
tebipenem pivoxil hydrobromide - Drug Profile
Product Description
Mechanism Of Action
History of Events
WCK-6777 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Pyelonephritis - Dormant Projects
Pyelonephritis - Discontinued Products
Pyelonephritis - Product Development Milestones
Featured News & Press Releases
Apr 06, 2022: Spero Therapeutics tebipenem pivoxil hydrobromide phase 3 data published in The New England Journal of Medicine
Jan 03, 2022: Spero Therapeutics announces FDA acceptance and Priority Review of New Drug Application for Tebipenem HBr for the treatment of complicated urinary tract infections including pyelonephritis
Oct 28, 2021: Spero Therapeutics submits new drug application to U.S. FDA for tebipenem HBr for the treatment of complicated urinary tract infections including pyelonephritis
Sep 16, 2021: Spero Therapeutics to present data at IDWeek 2021
Dec 16, 2020: Class 2 medicines recall: Merck Sharp & Dohme, Zerbaxa 1g/0.5g powder for concentrate for solution for infusion
Oct 21, 2020: Key highlights include data on NUZYRA as an alternative to standard of care to reduce clostridioides difficile infections and real-world experience with NUZYRA for nontuberculous mycobacterial and MDR/XDR gram negative infections
Oct 16, 2020: Spero Therapeutics to present data on tebipenem HBr at IDWeek 2020
Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Zavicefta
Sep 08, 2020: Spero Therapeutics announces positive topline results from its phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis
Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta
Apr 20, 2020: Wockhardt receives US FDA Qualified Infectious Disease Product designation for WCK 6777, a first ever once-a-day •-lactam enhancer class antibiotic
Feb 25, 2020: Allecra Therapeutics announces positive top-line results for Phase 3 ALLIUM clinical trial of EXBLIFEP for complicated urinary tract infections
Sep 03, 2019: Allecra Therapeutics to present data at ASM/ESCMID 2019 Conference on drug development to meet the challenge of antimicrobial resistance
Jul 29, 2019: Merck receives positive EU CHMP opinion for ZERBAXA 3g dose (ceftolozane and tazobactam) for the treatment of adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)
Apr 15, 2019: Paratek Pharmaceuticals broadens clinical profile of NUZYRA (Omadacycline) with New ECCMID 2019 Data Presentations
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pyelonephritis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pyelonephritis - Pipeline by Achaogen Inc (Inactive), 2022
Pyelonephritis - Pipeline by Allecra Therapeutics GmbH, 2022
Pyelonephritis - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Pyelonephritis - Pipeline by Iterum Therapeutics Plc, 2022
Pyelonephritis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, 2022
Pyelonephritis - Pipeline by Meiji Seika Pharma Co Ltd, 2022
Pyelonephritis - Pipeline by Melinta Therapeutics Inc, 2022
Pyelonephritis - Pipeline by Merck & Co Inc, 2022
Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, 2022
Pyelonephritis - Pipeline by Nabriva Therapeutics Plc, 2022
Pyelonephritis - Pipeline by Paratek Pharmaceuticals Inc, 2022
Pyelonephritis - Pipeline by Pfizer Inc, 2022
Pyelonephritis - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Pyelonephritis - Pipeline by VenatoRx Pharmaceuticals Inc, 2022
Pyelonephritis - Pipeline by Wockhardt Ltd, 2022
Pyelonephritis - Pipeline by XuanZhu Biological Technology Co Ltd, 2022
Pyelonephritis - Dormant Projects, 2022
Pyelonephritis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Pyelonephritis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Types, 2022

Companies Mentioned
• Achaogen Inc (Inactive)
• Allecra Therapeutics GmbH
• Entasis Therapeutics Holdings Inc
• Iterum Therapeutics Plc
• Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
• Meiji Seika Pharma Co Ltd
• Melinta Therapeutics Inc
• Merck & Co Inc
• MerLion Pharmaceuticals Pte Ltd
• Nabriva Therapeutics Plc
• Paratek Pharmaceuticals Inc
• Pfizer Inc
• Qilu Pharmaceutical Co Ltd
• VenatoRx Pharmaceuticals Inc
• Wockhardt Ltd
• XuanZhu Biological Technology Co Ltd